Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug;28(4):637-53.
doi: 10.1016/j.bpg.2014.07.008. Epub 2014 Jul 11.

Non-alcoholic fatty liver disease, obesity and the metabolic syndrome

Peter Dietrich  1 , Claus Hellerbrand  2
Affiliations
Review

Non-alcoholic fatty liver disease, obesity and the metabolic syndrome

Peter Dietrich et al. Best Pract Res Clin Gastroenterol. 2014 Aug.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is now recognized as the most common cause of chronic liver disease worldwide. Its prevalence has increased to more than 30% of adults in developed countries and its incidence is still rising. The majority of patients with NAFLD have simple steatosis but in up to one third of patients, NAFLD progresses to its more severe form nonalcoholic steatohepatitis (NASH). NASH is characterized by liver inflammation and injury thereby determining the risk to develop liver fibrosis and cancer. NAFLD is considered the hepatic manifestation of the metabolic syndrome. However, the liver is not only a passive target but affects the pathogenesis of the metabolic syndrome and its complications. Conversely, pathophysiological changes in other organs such as in the adipose tissue, the intestinal barrier or the immune system have been identified as triggers and promoters of NAFLD progression. This article details the pathogenesis of NAFLD along with the current state of its diagnosis and treatment.

Keywords: Metabolic syndrome; Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH).

PubMed Disclaimer